Evaluation and Comparison of Macular and Choroidal Thickness after Intracameral Moxifloxacin for Prevention of Postcataract Endophthalmitis

Abstract

Purpose : To evaluate the effect of intracameral moxifloxacin in macular and choroidal thickness.

Methods : A randomized clinical trial was performed at the University of Campinas(UNICAMP) in Brazil. Patients undergoing phacoemulsification surgery were divided into two groups. The first group(A) received 0.03ml intracameral moxifloxacin at the end of phacoemulsification surgery, while the second group(B) received no antibiotics intracamerally. Both groups applied eyedrops(moxifloxacin-dexamethasone) as the usual protocol in the postoperative care. Investigators’ evaluations of the patients were masked. Each patient was examined using Spectral Domain-Optical Coherence Tomography(SPECTRALIS®OCT) in the preoperative period, on the 30th postoperative day, and on the 60th postoperative day. Data was collected on central macular and choroidal thickness using enhanced depth imaging(EDI-OCT) measurement. Exclusion criteria were any macular changes prior to the surgery (including epiretinal membrane, macular edema, drusen), diabetic patients, and any complications during the cataract surgery.

Results : A total of 93 patients participated in this study(49 in group A and 45 in group B). The mean age was 68.9±10.49 years(36-88 years) for Group A and 68.88±11.15 years(40-92 years) for B. There was no statistical difference between the groups in terms of demographics(p=0.9878).
Evaluating the baseline parameters: there was no statistical difference between the groups in terms of central macular thickness(p=0.8275) or choroid thickness(p=0.5489); mean central macular thickness was 267.6±27.48 μm in A, and 266.5±21.62 μm in B. EDI values were 208.2±40.13 μm in A and 202.1±56.31 μm in B.
During the follow up, no statistical differences were detected in either of the two parameters assessed on the 30th postoperative day or for the 60th postoperative day.
On the 30th postoperative day, central macular thickness was 8.69±14.67 μm in A and 10.26±22.44 μm in B(p=0.6903); EDI was 1.71±16.06 μm in A and 3.74±16.15 in B(p=0.5479).
On the 60th postoperative day, central macular thickness was 19.11±38.77 μm in A and 17.14±53.68 μm in B(p=0.8467); EDI was 5.20±21.55 μm in A and 5.24±15.80 in B(p=0.9932).
There was no cases of endophthalmitis.

Conclusions : Intracameral moxifloxacin was safe for the macula as there were no significant changes in macula or choroidal thickness after the procedure.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.